首页> 中文期刊> 《中国医药导报》 >妥布霉素地塞米松联合氯替泼诺治疗前葡萄膜炎的疗效及对血清IgG、IgA和IgE的影响

妥布霉素地塞米松联合氯替泼诺治疗前葡萄膜炎的疗效及对血清IgG、IgA和IgE的影响

         

摘要

Objective To investigate the efficacy of Tobramycin Dexamethasone combined with Chlorine for treating with anterior uveitis and its impact on serum IgG, IgA and IgE. Methods 72 patients with anterior uveitis were randomly divided into study group and control group, the study group was treated with Tobramycin Dexamethasone combined Chlorine, while the control group was given Tobramycin Dexamethasone. All of the patients were followed up for six weeks. The clinical efficacy, healing time, side effects, serum IgG, IgA and IgE changes were compared between the two groups. Results The clinical efficacy of the study group was significantly better than the control group, the healing time was shorter than the control group, the incidence of adverse reactions was 2.78%, lower than 16.67% of the control group, there were significant differences between the two groups (P < 0.05); and after the treatment, the serum IgG and IgE levels in the study group were significantly lower than the control group, IgA was higher than the control group (P < 0.05). Conclusion The efficacy of Tobramycin Dexamethasone combined with Chlorine for treating with anterior uveitis is certainly better than Tobramycin Dexamethasone alone, and it can significantly reduce the serum IgG, IgA and IgE levels, and it should be widely applied in clinic.%目的 探讨妥布霉素地塞米松联合氯替泼诺治疗前葡萄膜炎的疗效及对血清IgG、IgA和IgE的影响.方法收集72例前葡萄膜炎患者,随机分为研究组与对照组,研究组患者应用妥布霉素地塞米松联合氯替泼诺治疗,而对照组单用妥布霉素地塞米松治疗,观察2个疗程后比较两组患者临床疗效、治愈时间、不良反应发生情况、治疗前后血清IgG、IgA和IgE变化情况.结果研究组临床疗效明显优于对照组,治愈时间明显短于对照组,不良反应发生率(2.78%)明显低于对照组(16.67%),两组相比差异均有统计学意义(均P < 0.05);且治疗后研究组血清IgG及IgE水平明显低于对照组、IgA高于对照组,两组相比差异有统计学意义(P < 0.05).结论妥布霉素地塞米松联合氯替泼诺治疗前葡萄膜炎疗效肯定,优于单用妥布霉素地塞米松,且能明显降低血清IgG、IgA和IgE水平,值得临床推广应用.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号